Tagged with Strategy

Taiwan Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have to play in more effective COVID-19 diagnostics.   Given our status as a raw materials developer, we see an opportunity…

Mexico UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region carries for the firm.   The upcoming three years are crucial and UCB Mexico wants to play a role elevating…

China Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly adapting their portfolio strategies to launch products on the large but challenging domestic Chinese market.   I-Mab: Observing Competitors and Staying Flexible I-Mab already has a fairly advanced China portfolio, with…

UAE Working non-stop to catch up with its footprint in other regions, Boston Scientific is investing heavily in the MENA markets. Tarek El Rahbani, managing director for the region, shares the company’s change in strategy, opting to have enhanced direct presence in the region. Moreover, he explains why Boston Scientific’s therapies…

Belgium Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company was acquired by Johnson & Johnson. Sonja Willems, managing director of Janssen Benelux, discusses the company’s response to the COVID-19…

Morocco Karim Lahlou of Moroccan pharma manufacturer Iberma discusses the firm’s evolution in recent years, the abundant opportunities for Iberma in the African market, and why strong international partnerships will help the company thrive in the future.   While we continue developing new business ideas, we are capitalizing on our stable…

USA Aldo Donati, CEO for Swiss firm IBSA in the USA, discusses the challenges for European mid-caps in expanding to the US market and his portfolio strategy for ensuring future successes for IBSA USA.   In the global economy we are operating in, the US market cannot be ignored and if…

Morocco Mohamed El Bouhmadi, president and CEO of Zenith Pharma, walks us through the company’s evolution since we last met in 2015. He shares his strategy to position the company as the Moroccan champion in Africa through in-house product development and production as well as implementing an export strategy in close…

Belgium Karel Van De Sompel, country manager of Pfizer in Belgium and Luxembourg and chairman of Pharma.be, highlights the key changes he sees in today’s pharma market which revolve around the increasing trend of personalized medicine, digitalization, big healthcare data, and stakeholder partnerships. Additionally, Van De Sompel also elaborates on Pfizer’s…

China I-Mab Biopharma CFO Jielun Zhu recaps the exciting milestones for the company over the past year since our last interview in May 2019, including most notably their NASDAQ IPO in January 2020, as well as shares some insights on the NASDAQ IPO experience.   Before the IPO, we might have…

Coronavirus With the global coronavirus pandemic still ongoing and teleworking having become the new normal, pharma executives from across the world are giving us their insights into how they are managing in the age of confinement to ensure continued employee welfare and the safe supply of medications to the patients and…

Morocco Taher Hassen, GM for Morocco and Tunisia at Merck, gives insights into navigating market access in the complex Moroccan pharma market, outlines, the challenge of introducing biosimilars, and the enduring importance of North Africa for Merck.   Morocco is a very attractive country in terms of investment, given its stable…